Table (1):
patient demographics (age, sex, and ethnicity). Tumor characteristics, radiotherapy and chemotherapy.
| Characteristic | Result |
|---|---|
| Number of patients | 46 |
| Median age at time of RT | 59 (39-78) |
| Sex, n (%) | |
| Male | 42 (91%) |
| Female | 4 (9%) |
| Ethnicity, n (%) | |
| Caucasian | 41 (89%) |
| Black | 3 (7%) |
| Hispanic | 1 (2%) |
| Asian | 1 (2%) |
| Tumor site, n (%) | |
| Base of tongue | 26 (57%) |
| Tonsils | 20 (43%) |
| TNM | |
| T1 | 3 (22%) |
| T2 | 17 (37%) |
| T3 | 10 (22%) |
| T4 | 16 (35%) |
| N1 | 5 (11%) |
| N2A | 3 (7%) |
| N2B | 17 (37%) |
| N2C | 20 (43%) |
| N3 | 1 (2%) |
| Dose prescribed | 70 Gy |
| Number of fractions | 33 |
| Type of RT n, (%) | |
| IMRT | 24 (52%) |
| IMPT | 22 (48%) |
| Induction Chemotherapy, n (%) | |
| Yes | 10 (22%) |
| No | 36 (78%) |
| Type of induction chemotherapy, n (%) | |
| PCC | 3 (7%) |
| TPF | 4 (9%) |
| Platinum/Taxanes | 2 (4%) |
| Platinum single agent | 1 (2%) |
| Concurrent chemotherapy, n (%) | |
| Yes | 45 (98%) |
| No | 1 (2%) |
| Type of concurrent chemotherapy, n (%) | |
| Platinum single agent | 39 (87%) |
| Taxanes | 1 (2%) |
| Platinum/Taxanes | 1 (2%) |
| Cetuximab | 4 (9%) |
TPF: docetaxel, cisplatin and fluorouracil
PCC: Paclitaxel, Carboplatin and Cetuximab